Coherus BioSciences (CHRS) Stock Forecast, Price Target & Predictions
CHRS Stock Forecast
Coherus BioSciences stock forecast is as follows: an average price target of $9.00 (represents a 718.18% upside from CHRS’s last price of $1.10) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
CHRS Price Target
CHRS Analyst Ratings
Hold
Coherus BioSciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 14, 2022 | - | J.P. Morgan | $11.00 | $7.79 | 41.21% | 900.00% |
Jun 13, 2022 | Ashwani Verma | UBS | $7.00 | $6.19 | 13.09% | 536.36% |
10
Coherus BioSciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $1.10 | $1.10 | $1.10 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 16, 2024 | UBS | Buy | Neutral | Downgrade |
May 30, 2024 | Cowen & Co. | Buy | Buy | Hold |
May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Mar 28, 2023 | UBS | Neutral | Buy | Upgrade |
Jun 13, 2022 | UBS | - | Neutral | Initialise |
Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Apr 26, 2022 | J.P. Morgan | - | Neutral | Downgrade |
10
Coherus BioSciences Financial Forecast
Coherus BioSciences Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $91.52M | $74.57M | $58.72M | $32.44M | $45.35M | $45.42M | $60.15M | $60.12M | $73.37M | $82.50M | $87.64M | $83.03M | $110.42M | $113.55M | $135.67M | $116.18M | $123.86M | $111.68M | $83.43M | $37.10M | $161.00K | $12.36M |
Avg Forecast | $97.15M | $81.35M | $74.20M | $66.55M | $44.95M | $58.98M | $62.06M | $81.70M | $96.89M | $81.78M | $50.47M | $46.29M | $47.69M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $143.23K | $10.51M |
High Forecast | $116.57M | $97.62M | $89.04M | $66.86M | $66.67M | $60.81M | $74.47M | $81.70M | $111.89M | $81.78M | $60.57M | $55.55M | $57.23M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $171.87K | $12.61M |
Low Forecast | $84.79M | $71.00M | $64.76M | $66.23M | $31.49M | $57.15M | $54.16M | $81.70M | $81.90M | $81.78M | $44.05M | $40.40M | $41.62M | $56.69M | $62.04M | $69.54M | $82.61M | $90.69M | $87.04M | $96.20M | $114.89M | $124.01M | $102.52M | $119.44M | $125.09M | $100.72M | $64.63M | $36.96M | $114.58K | $8.41M |
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.91% | 1.16% | 0.70% | 0.95% | 0.80% | 0.97% | 0.86% | 0.89% | 0.91% | 1.01% | 0.86% | 0.96% | 0.92% | 1.32% | 0.97% | 0.99% | 1.11% | 1.29% | 1.00% | 1.12% | 1.18% |
Forecast
Coherus BioSciences EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
EBITDA | - | - | - | - | - | - | - | - | $-68.36M | $-32.01M | $-34.54M | $-66.02M | $-49.48M | $-78.11M | $-42.68M | $-80.13M | $-39.10M | $-31.86M | $-23.28M | $-166.45M | $17.27M | $34.47M | $66.48M | $41.54M | $46.81M | $53.20M | $28.73M | $-15.10M | $-71.54M | $-63.83M |
Avg Forecast | $-36.92M | $-30.92M | $-28.20M | $-25.29M | $-17.09M | $-22.42M | $-23.59M | $-88.66M | $-36.82M | $-31.08M | $-19.18M | $-70.09M | $-43.71M | $-21.61M | $-23.64M | $-55.41M | $-31.48M | $-34.56M | $-33.17M | $-5.84B | $-43.78M | $-47.26M | $-39.07M | $47.48M | $-47.67M | $-38.39M | $-24.63M | $-20.88M | $-62.66M | $-52.60M |
High Forecast | $-32.22M | $-26.98M | $-24.61M | $-25.17M | $-11.97M | $-21.72M | $-20.58M | $-70.93M | $-31.12M | $-31.08M | $-16.74M | $-56.07M | $-34.97M | $-21.61M | $-23.64M | $-44.33M | $-31.48M | $-34.56M | $-33.17M | $-4.67B | $-43.78M | $-47.26M | $-39.07M | $56.97M | $-47.67M | $-38.39M | $-24.63M | $-16.70M | $-50.13M | $-42.08M |
Low Forecast | $-44.30M | $-37.10M | $-33.84M | $-25.41M | $-25.34M | $-23.11M | $-28.30M | $-106.40M | $-42.53M | $-31.08M | $-23.02M | $-84.11M | $-52.45M | $-21.61M | $-23.64M | $-66.49M | $-31.48M | $-34.56M | $-33.17M | $-7.01B | $-43.78M | $-47.26M | $-39.07M | $37.98M | $-47.67M | $-38.39M | $-24.63M | $-25.05M | $-75.19M | $-63.11M |
Surprise % | - | - | - | - | - | - | - | - | 1.86% | 1.03% | 1.80% | 0.94% | 1.13% | 3.62% | 1.81% | 1.45% | 1.24% | 0.92% | 0.70% | 0.03% | -0.39% | -0.73% | -1.70% | 0.88% | -0.98% | -1.39% | -1.17% | 0.72% | 1.14% | 1.21% |
Forecast
Coherus BioSciences Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
Net Income | - | - | - | - | - | - | - | - | $-79.65M | $-39.64M | $-42.87M | $-74.78M | $-66.25M | $-92.85M | $-56.29M | $-111.24M | $-51.52M | $-38.53M | $-29.90M | $-172.95M | $9.71M | $27.93M | $59.03M | $35.57M | $39.23M | $47.04M | $23.57M | $-20.00M | $-74.78M | $-65.39M |
Avg Forecast | $-5.76M | $-5.76M | $-5.76M | $-5.76M | $-35.21M | $-18.82M | $-28.65M | $-98.66M | $-22.90M | $-44.97M | $-72.45M | $-77.99M | $-51.12M | $-82.31M | $-89.99M | $-61.65M | $-52.82M | $-39.73M | $-24.11M | $-6.07B | $24.68M | $42.04M | $33.20M | $40.65M | $80.89M | $54.62M | $-4.25M | $-27.67M | $-65.50M | $-53.88M |
High Forecast | $-4.81M | $-4.81M | $-4.81M | $-4.38M | $-29.38M | $-15.71M | $-23.91M | $-78.93M | $-19.11M | $-37.53M | $-60.47M | $-62.39M | $-40.90M | $-82.31M | $-89.99M | $-49.32M | $-52.82M | $-39.73M | $-24.11M | $-4.86B | $24.68M | $42.04M | $33.20M | $48.78M | $80.89M | $54.62M | $-4.25M | $-22.13M | $-52.40M | $-43.10M |
Low Forecast | $-7.26M | $-7.26M | $-7.26M | $-7.14M | $-44.36M | $-23.71M | $-36.10M | $-118.39M | $-28.86M | $-56.66M | $-91.29M | $-93.59M | $-61.35M | $-82.31M | $-89.99M | $-73.98M | $-52.82M | $-39.73M | $-24.11M | $-7.28B | $24.68M | $42.04M | $33.20M | $32.52M | $80.89M | $54.62M | $-4.25M | $-33.20M | $-78.60M | $-64.65M |
Surprise % | - | - | - | - | - | - | - | - | 3.48% | 0.88% | 0.59% | 0.96% | 1.30% | 1.13% | 0.63% | 1.80% | 0.98% | 0.97% | 1.24% | 0.03% | 0.39% | 0.66% | 1.78% | 0.88% | 0.48% | 0.86% | -5.55% | 0.72% | 1.14% | 1.21% |
Forecast
Coherus BioSciences SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
SG&A | - | - | - | - | - | - | - | - | $48.95M | $48.22M | $45.14M | $49.15M | $53.62M | $44.83M | $51.28M | $48.75M | $50.05M | $39.92M | $40.34M | $39.39M | $37.69M | $31.98M | $34.05M | $35.35M | $36.07M | $31.83M | $36.46M | $32.68M | $18.80M | $11.40M |
Avg Forecast | $55.55M | $46.51M | $42.43M | $38.05M | $25.70M | $33.72M | $35.48M | $50.06M | $55.40M | $46.76M | $28.86M | $39.57M | $27.27M | $32.42M | $35.47M | $31.28M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $40.40M | $71.52M | $57.59M | $36.95M | $21.13M | $81.89K | $9.39M |
High Forecast | $66.66M | $55.81M | $50.91M | $38.23M | $38.12M | $34.77M | $42.58M | $60.07M | $63.98M | $46.76M | $34.63M | $47.49M | $32.72M | $32.42M | $35.47M | $37.54M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $48.48M | $71.52M | $57.59M | $36.95M | $21.13M | $98.27K | $11.27M |
Low Forecast | $48.48M | $40.59M | $37.03M | $37.87M | $18.01M | $32.68M | $30.97M | $40.05M | $46.83M | $46.76M | $25.19M | $31.66M | $23.80M | $32.42M | $35.47M | $25.03M | $47.24M | $51.85M | $49.77M | $55.01M | $65.69M | $70.91M | $58.62M | $32.32M | $71.52M | $57.59M | $36.95M | $21.13M | $65.51K | $7.51M |
Surprise % | - | - | - | - | - | - | - | - | 0.88% | 1.03% | 1.56% | 1.24% | 1.97% | 1.38% | 1.45% | 1.56% | 1.06% | 0.77% | 0.81% | 0.72% | 0.57% | 0.45% | 0.58% | 0.88% | 0.50% | 0.55% | 0.99% | 1.55% | 229.60% | 1.21% |
Forecast
Coherus BioSciences EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 17 | Mar 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 2 | 5 | 4 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 8 |
EPS | - | - | - | - | - | - | - | - | $-0.71 | $-0.00 | $-0.49 | $-0.94 | $-0.85 | $-1.19 | $-0.73 | $-1.44 | $-0.67 | $-0.49 | $-0.40 | $-2.37 | $0.13 | $0.39 | $0.83 | $0.50 | $0.56 | $0.67 | $0.34 | $-0.29 | $-1.54 | $-1.67 |
Avg Forecast | $-0.05 | $-0.05 | $-0.05 | $-0.05 | $-0.31 | $-0.16 | $-0.25 | $-0.25 | $-0.20 | $-0.39 | $-0.63 | $-0.72 | $-0.98 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-1.20 | $-1.17 |
High Forecast | $-0.04 | $-0.04 | $-0.04 | $-0.04 | $-0.26 | $-0.14 | $-0.21 | $-0.21 | $-0.17 | $-0.33 | $-0.52 | $-0.60 | $-0.82 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-0.96 | $-0.94 |
Low Forecast | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.39 | $-0.21 | $-0.31 | $-0.32 | $-0.25 | $-0.49 | $-0.79 | $-0.91 | $-1.24 | $-0.72 | $-0.78 | $-0.65 | $-0.46 | $-0.35 | $-0.21 | $-0.21 | $0.21 | $0.37 | $0.29 | $0.52 | $0.70 | $0.48 | $-0.04 | $-0.47 | $-1.44 | $-1.40 |
Surprise % | - | - | - | - | - | - | - | - | 3.57% | 0.00% | 0.78% | 1.30% | 0.87% | 1.66% | 0.93% | 2.23% | 1.46% | 1.42% | 1.90% | 11.47% | 0.60% | 1.07% | 2.87% | 0.97% | 0.79% | 1.41% | -9.19% | 0.62% | 1.28% | 1.43% |
Forecast
Coherus BioSciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SPRO | Spero Therapeutics | $1.20 | $10.00 | 733.33% | Buy |
CHRS | Coherus BioSciences | $1.10 | $9.00 | 718.18% | Hold |
CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
TIL | Instil Bio | $23.36 | $78.25 | 234.97% | Hold |
NUVB | Nuvation Bio | $2.58 | $6.75 | 161.63% | Buy |
ASMB | Assembly Biosciences | $15.02 | $35.50 | 136.35% | Buy |
NXTC | NextCure | $1.30 | $3.00 | 130.77% | Buy |
ACHL | Achilles Therapeutics | $1.07 | $2.00 | 86.92% | Buy |
BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |